Brief: PhaseBio Doses First Patient In Vangard Phase 2 Clinical Trial

PhaseBio Pharmaceuticals

16/07/2020 21:14

July 16 (Reuters) - PhaseBio Pharmaceuticals Inc  PHAS.O :
    * PHASEBIO DOSES FIRST PATIENT IN VANGARD PHASE 2 CLINICAL
TRIAL
TO EVALUATE PB1046 FOR HOSPITALIZED COVID-19 PATIENTS
    * PHASEBIO DOSES FIRST PATIENT IN VANGARD PHASE 2 CLINICAL
TRIAL
TO EVALUATE PB1046 FOR HOSPITALIZED COVID-19 PATIENTS

Source text for Eikon:  ID:nBw4FjxhPa 
Further company coverage:  PHAS.O 

 ((Reuters.Briefs@thomsonreuters.com;))